266 related articles for article (PubMed ID: 25580775)
1. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park CY; Cho YM; Ku BJ; Ahn CW; Cha BS; Min KW; Sung YA; Baik SH; Lee KW; Yoon KH; Lee MK; Park SW
Diabetes Obes Metab; 2015 Jun; 17(6):599-602. PubMed ID: 25580775
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-blind, Phase III Trial of Lobeglitazone Add-on to Metformin in Type 2 Diabetes (SENSITIZE INDIA).
Joshi S; Tandon M; Kodgule R; Wu W; Jadhao V; Suryawanshi S; Barkate H
J Assoc Physicians India; 2024 Jan; 72(1):32-42. PubMed ID: 38736072
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
[TBL] [Abstract][Full Text] [Related]
4. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park SW; Yoon KH; Min KW; Song KH; Park KS; Park JY; Park IB; Chung CH; Baik SH; Choi SH; Lee HW; Lee IK; Kim DM; Lee MK
Diabetes Obes Metab; 2015 May; 17(5):511-5. PubMed ID: 25523633
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Ryang S; Kim SS; Bae JC; Han JM; Kwon SK; Kim YI; Nam-Goong IS; Kim ES; Kim MK; Lee CW; Yoo S; Koh G; Kwon MJ; Park JH; Kim IJ
Diabetes Obes Metab; 2022 Sep; 24(9):1800-1809. PubMed ID: 35581902
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
Kim SG; Kim DM; Woo JT; Jang HC; Chung CH; Ko KS; Park JH; Park YS; Kim SJ; Choi DS
PLoS One; 2014; 9(4):e92843. PubMed ID: 24736628
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
Kim SG; Kim KJ; Yoon KH; Chun SW; Park KS; Choi KM; Lim S; Mok JO; Lee HW; Seo JA; Cha BS; Kim MK; Shon HS; Choi DS; Kim DM
Diabetes Obes Metab; 2020 Oct; 22(10):1869-1873. PubMed ID: 32406573
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study.
Kim SH; Kim SG; Kim DM; Woo JT; Jang HC; Chung CH; Ko KS; Park JH; Park YS; Kim SJ; Choi DS
Diabetes Res Clin Pract; 2015 Dec; 110(3):e27-30. PubMed ID: 26458774
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
[TBL] [Abstract][Full Text] [Related]
20. Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Wang Y; Jiang C; Dong X; Chen M; Gu Q; Zhang L; Fu Y; Pan T; Bi Y; Song W; Xu J; Lu W; Sun X; Ye Z; Zhang D; Peng L; Lin X; Dai W; Wang Q; Yang W
Diabetes Obes Metab; 2024 Jul; 26(7):2774-2786. PubMed ID: 38618970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
